FindTrial
Sign In

RD13-02 cell infusion

DRUG7 trials

Sponsors

He Huang, MEI HENG, Xiaoyu Zhu, Kai Lin Xu，MD, Henan Cancer Hospital

Conditions

CART TherapyCD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesHematologic DiseasesHematologic MalignanciesHematologic NeoplasmsNK T-Cell LymphomaNeoplasmsNeoplasms by Site

Early Phase 1

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
CompletedNCT05716113
He HuangHematologic Diseases, Hematologic Neoplasms, Neoplasms +1
Start: 2023-02-09End: 2024-08-31Updated: 2024-11-21
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
CompletedNCT05895994
MEI HENGHematologic Diseases, Hematologic Neoplasms, Neoplasms +1
Start: 2023-03-10End: 2024-12-31Updated: 2026-02-03
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
CompletedNCT05902845
Xiaoyu ZhuHematologic Diseases, Hematologic Neoplasms, Neoplasms
Start: 2023-04-30End: 2024-08-31Updated: 2024-11-21
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
CompletedNCT05907603
Kai Lin Xu，MDHematologic Diseases, Hematologic Neoplasms, Neoplasms
Start: 2023-03-08End: 2024-08-31Updated: 2024-11-21
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
CompletedNCT05923541
Henan Cancer HospitalHematologic Malignancies
Start: 2023-06-26End: 2024-08-31Updated: 2024-11-22
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
Active, not recruitingNCT07142161
Nanjing Bioheng Biotech Co., Ltd.Type 1 Diabetes
Start: 2025-07-20End: 2026-12-25Target: 3Updated: 2025-08-26

Phase 1

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
RecruitingNCT06732492
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCART Therapy, CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies, NK T-Cell Lymphoma
Start: 2024-10-31End: 2027-12-31Target: 10Updated: 2024-12-13

Related Papers

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)
Blood2025-11-03
A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)
Blood2025-11-03
CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies
Blood2025-11-03
A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
Blood2024-11-051 citations
Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT
Blood2023-11-023 citations